Royal Bank of Canada’s Loncar China BioPharma ETF CHNA Stock Holding History

Royal Bank of Canada’s Portfolio CHNA Stock Details CHNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-100	Closed	-$4K	–	7785
2021 Q1	$4K	Buy	+100	New	+$3.73K	﹤0.01%	7124
2020 Q2	–	Sell	-100	Closed	-$2K	–	7010
2020 Q1	$2K	Buy	+100	New	+$2.47K	﹤0.01%	6354

Other funds holding CHNA

FEM

Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

MCM

MV Capital Management Bethesda, Maryland $1.13B AUM 25.77% 1-Year Est. Return

Royal Bank of Canada's CHNA Position: Q2 2021 in Review

Royal Bank of Canada sold out of Loncar China BioPharma ETF (CHNA) in Q2 2021, closing a stake of 100 shares — an estimated $4K sold.

Royal Bank of Canada first reported a position in CHNA in Q1 2020 and held it in 2 quarters. The position peaked at $4K in Q1 2021. 4 funds tracked by Wall St. Rank hold CHNA as of Q2 2021.

Royal Bank of Canada reported no remaining Loncar China BioPharma ETF position as of Q2 2021 after selling out during the quarter.
Royal Bank of Canada sold 100 Loncar China BioPharma ETF shares in Q2 2021, an estimated $4K.
Royal Bank of Canada first reported a position in Loncar China BioPharma ETF in Q1 2020 and held it in 2 quarters.
Royal Bank of Canada's Loncar China BioPharma ETF position peaked at $4K in Q1 2021.
4 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q2 2021.

Based on Royal Bank of Canada's 13F filing for Q2 2021, filed 16 Aug 2021.